Guidance for Ani Pharmaceuticals (ANIP)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | $9.19 – $9.69 | $9.07 | $1.08B – 1.14B | $1.09B | = Maintained | Details |
| 2026 | $8.83 – $9.34 | $8.64 | $1.05B – 1.12B | $1.03B | = Maintained | Details |
| 2025 | $6.27 – $6.62 | $6.34 | $768.00M – 793.00M | $769.60M | = Maintained | Details |
| 2025 | $6.12 – $6.49 | $5.56 | $756.00M – 776.00M | $724.90M | = Maintained | Details |
| 2024 | $4.90 – $5.05 | $4.72 | $594.00M – 602.00M | $590.30M | = Maintained | Details |
| 2024 | $4.26 – $4.67 | $4.48 | $520.00M – 542.00M | $535.11M | = Maintained | Details |
| 2024 | $4.26 – $4.67 | $4.33 | $520.00M – 542.00M | $506.20M | = Maintained | Details |
| 2023 | $3.62 – $4.11 | $3.32 | $425.00M – 445.00M | $402.90M | = Maintained | Details |
| Q2 2023 | $2.99 – $3.45 | $2.43 | $385.00M – 410.00M | $371.30M | = Maintained | Details |
| 2022 | $1.34 – $1.62 | $1.37 | $295.00M – 315.00M | $303.00M | = Maintained | Details |
| 2022 | $1.34 – $1.62 | $1.43 | $295.00M – 315.00M | $305.00M | = Maintained | Details |
| 2022 | $1.34 – $1.62 | $1.15 | $295.00M – 315.00M | $292.80M | = Maintained | Details |
| 2022 | N/A | N/A | $260.00M – 275.00M | $301.60M | = Maintained | Details |
| 2020 | $4.46 – $4.86 | $5.47 | $213.00M – 223.00M | $229.15M | = Maintained | Details |
| 2019 | $5.06 – $5.23 | $5.73 | $209.00M – 212.00M | $222.67M | = Maintained | Details |
| 2019 | $5.57 – $6.21 | $6.01 | $220.00M – 226.00M | $239.80M | Lowered |
Details |
| 2019 | N/A | N/A | $231.00M – 245.00M | $240.22M | = Maintained | Details |
| 2019 | $5.57 – $6.21 | $5.79 | $231.00M – 245.00M | $243.37M | = Maintained | Details |
| 2018 | $4.80 – $5.27 | $4.91 | $195.00M – 205.00M | $200.04M | = Maintained | Details |
| 2018 | $4.80 – $5.27 | $5.74 | $195.00M – 205.00M | N/A | Lowered |
Details |
| 2018 | $5.43 – $6.08 | $4.76 | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2017 | $3.58 – $3.94 | $3.79 | $181.00M – 190.00M | $182.55M | = Maintained | Details |
| 2017 | $3.58 – $3.94 | N/A | $181.00M – 190.00M | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2016 | $4.00 – $4.25 | $4.09 | $128.00M – 134.00M | $126.10M | = Maintained | Details |
| 2016 | $4.00 – $4.25 | $3.63 | $119.00M – 134.00M | $124.20M | Raised |
Details |
| 2016 | $3.54 – $3.91 | $3.41 | $119.00M – 134.00M | $117.87M | = Maintained | Details |
| 2016 | N/A | N/A | $105.00M – 120.00M | $91.80M | Raised |
Details |
| 2015 | $2.83 – $2.96 | $2.44 | $75.50M – 78.30M | $82.40M | = Maintained | Details |
| 2015 | $2.48 – $2.72 | $2.67 | $80.00M – 88.00M | $91.60M | = Maintained | Details |
| Q4 2015 | $0.60 – $0.76 | $0.70 | $17.20M – 20.00M | $22.70M | = Maintained | Details |
| Q4 2014 | $0.60 – $0.65 | $0.45 | $17.00M – 18.00M | $15.20M | = Maintained | Details |


Lowered
Raised